TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vitrafy Life Sciences Ltd. ( (AU:VFY) ) has issued an update.
Vitrafy Life Sciences Limited has announced the release of 8,744,376 fully paid ordinary shares from mandatory escrow on 21 November 2025, in accordance with ASX Listing Rule 3.10A. Following the release, 25% of these securities will no longer be subject to escrow restrictions, while the remaining 75% will continue under voluntary escrow until the company’s audited accounts for the financial year ending 30 June 2026 are released. This move may impact the company’s stock liquidity and market perception, providing stakeholders with a clearer view of the company’s financial health and operational strategy.
The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.10 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited (ASX: VFY) is a company specializing in advanced cryopreservation technology, which significantly enhances cell survival rates across various applications such as blood platelets, cell and gene therapies, aquaculture, and bovine reproduction. The company offers comprehensive cryopreservation solutions through a managed service revenue model, leveraging its FDA-registered Smart Freezing and Smart Thawing devices, the LifeChain™ software platform, and Smart Packaging systems.
Average Trading Volume: 22,885
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$95.77M
For a thorough assessment of VFY stock, go to TipRanks’ Stock Analysis page.